SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity

Journal of Cell Biology

Volumn 193, Issue 7, 2011, Pages 1305-1319

  Rivera, Lee B ^a,b   Brekken, Rolf A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; ENDOGLIN; OSTEONECTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CELL MOVEMENT; INTEGRIN ALPHAV; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEONECTIN; PERICYTES; TRANSFORMING GROWTH FACTOR BETA1;

MUS;

EID: 79960239007     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201011143     Document Type: Article

References (86)

1. Aguirre, A.J., N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, M.S. Redston, and R.A. DePinho. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17:3112-3126.
2. 6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1. J. Cell Biol. 165:723-734.
3. Antonelli-Orlidge, A., K.B. Saunders, S.R. Smith, and P.A. D'Amore. 1989. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. USA. 86:4544-4548.
4. Arnold, S.A., L.B. Rivera, A.F. Miller, J.G. Carbon, S.P. Dineen, Y. Xie, D.H. Castrillon, E.H. Sage, P. Puolakkainen, A.D. Bradshaw, and R.A. Brekken. 2010. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech. 3:57-72.
5. Arthur, H.M., J. Ure, A.J. Smith, G. Renforth, D.I. Wilson, E. Torsney, R. Charlton, D.V. Parums, T. Jowett, D.A. Marchuk, et al. 2000. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 217:42-53.
6. Asano, Y., H. Ihn, M. Jinnin, Y. Mimura, and K. Tamaki. 2006a. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J. Invest. Dermatol. 126:1761-1769.
7. Asano, Y., H. Ihn, K. Yamane, M. Jinnin, and K. Tamaki. 2006b. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am. J. Pathol. 168:499-510.
8. Barbara, N.P., J.L. Wrana, and M. Letarte. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J. Biol. Chem. 274:584-594.
9. Barker, T.H., G. Baneyx, M. Cardó-Vila, G.A. Workman, M. Weaver, P.M. Menon, S. Dedhar, S.A. Rempel, W. Arap, R. Pasqualini, et al. 2005. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 280:36483-36493.
10. Benjamin, L.E., D. Golijanin, A. Itin, D. Pode, and E. Keshet. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165.
11. Bergers, G., S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287-1295.
12. Boeuf, S., M. Börger, T. Hennig, A. Winter, P. Kasten, and W. Richter. 2009. Enhanced ITM2A expression inhibits chondrogenic differentiation of mesenchymal stem cells. Differentiation. 78:108-115.
13. Bourdeau, A., D.J. Dumont, and M. Letarte. 1999. A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104:1343-1351.
14. Bradshaw, A.D. 2009. The role of SPARC in extracellular matrix assembly. J. Cell Commun. Signal. 3:239-246.
15. Chlenski, A., L.J. Guerrero, Q. Yang, Y. Tian, R. Peddinti, H.R. Salwen, and S.L. Cohn. 2007. SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene. 26:4513-4522.
16. Conley, B.A., R. Koleva, J.D. Smith, D. Kacer, D. Zhang, C. Bernabéu, and C.P. Vary. 2004. Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J. Biol. Chem. 279:27440-27449.
17. Courtoy, P.J., and J. Boyles. 1983. Fibronectin in the microvasculature: localization in the pericyte-endothelial interstitium. J. Ultrastruct. Res. 83:258-273.
18. Crisan, M., S. Yap, L. Casteilla, C.W. Chen, M. Corselli, T.S. Park, G. Andriolo, B. Sun, B. Zheng, L. Zhang, et al. 2008. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 3:301-313.
19. Daly, A.C., R.A. Randall, and C.S. Hill. 2008. Transforming growth factor betainduced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell. Biol. 28:6889-6902.
20. Darland, D.C., and P.A. D'Amore. 2001. TGF beta is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1/2 and endothelial cells. Angiogenesis. 4:11-20.
21. Delannet, M., F. Martin, B. Bossy, D.A. Cheresh, L.F. Reichardt, and J.L. Duband. 1994. Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development. 120:2687-2702.
22. Derynck, R., J.A. Jarrett, E.Y. Chen, and D.V. Goeddel. 1986. The murine transforming growth factor-beta precursor. J. Biol. Chem. 261:4377-4379.
23. Dickson, M.C., J.S. Martin, F.M. Cousins, A.B. Kulkarni, S. Karlsson, and R.J. Akhurst. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 121:1845-1854.
24. Eberhard, A., S. Kahlert, V. Goede, B. Hemmerlein, K.H. Plate, and H.G. Augustin. 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60:1388-1393.
25. Feinberg, M.W., M. Watanabe, M.A. Lebedeva, A.S. Depina, J. Hanai, T. Mammoto, J.P. Frederick, X.F. Wang, V.P. Sukhatme, and M.K. Jain. 2004. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J. Biol. Chem. 279:16388-16393.
26. Finnemann, S.C. 2003. Focal adhesion kinase signaling promotes phagocytosis of integrin-bound photoreceptors. EMBO J. 22:4143-4154.
27. Francki, A., K. Motamed, T.D. McClure, M. Kaya, C. Murri, D.J. Blake, J.G. Carbon, and E.H. Sage. 2003. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J. Cell. Biochem. 88:802-811.
28. Francki, A., T.D. McClure, R.A. Brekken, K. Motamed, C. Murri, T. Wang, and E.H. Sage. 2004. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J. Cell. Biochem. 91:915-925.
29. Galliher, A.J., and W.P. Schiemann. 2006. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8:R42.
30. Gao, R., and D.R. Brigstock. 2004. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J. Biol. Chem. 279:8848-8855.
31. Gerhardt, H., and H. Semb. 2008. Pericytes: gatekeepers in tumour cell metastasis? J. Mol. Med. 86:135-144.
32. Gougos, A., S. St Jacques, A. Greaves, P.J. O'Connell, A.J. d'Apice, H.J. Bühring, C. Bernabeu, J.A. van Mourik, and M. Letarte. 1992. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol. 4:83-92.
33. Goumans, M.J., G. Valdimarsdottir, S. Itoh, F. Lebrin, J. Larsson, C. Mummery, S. Karlsson, and P. ten Dijke. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell. 12:817-828.
34. Guasch, G., M. Schober, H.A. Pasolli, E.B. Conn, L. Polak, and E. Fuchs. 2007. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell. 12:313-327.
35. Guerrero-Esteo, M., T. Sanchez-Elsner, A. Letamendia, and C. Bernabeu. 2002. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem. 277:29197-29209.
36. Hasselaar, P., and E.H. Sage. 1992. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49:272-283.
37. Hellström, M., H. Gerhardt, M. Kalén, X. Li, U. Eriksson, H. Wolburg, and C. Betsholtz. 2001. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153:543-553.
38. Helmlinger, G., F. Yuan, M. Dellian, and R.K. Jain. 1997. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3:177-182.
39. Hirschi, K.K., S.A. Rohovsky, and P.A. D'Amore. 1998. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 141:805-814.
40. Imai, K., A. Hiramatsu, D. Fukushima, M.D. Pierschbacher, and Y. Okada. 1997. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem. J. 322:809-814.
41. Iruela-Arispe, M.L., T.F. Lane, D. Redmond, M. Reilly, R.P. Bolender, T.J. Kavanagh, and E.H. Sage. 1995. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell. 6:327-343.
42. Klemke, R.L., M. Yebra, E.M. Bayna, and D.A. Cheresh. 1994. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J. Cell Biol. 127:859-866.
43. Kojima, S., P.C. Harpel, and D.B. Rifkin. 1991. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113:1439-1445.
44. Koleva, R.I., B.A. Conley, D. Romero, K.S. Riley, J.A. Marto, A. Lux, and C.P. Vary. 2006. Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J. Biol. Chem. 281:25110-25123.
45. Kornberg, L., H.S. Earp, J.T. Parsons, M. Schaller, and R.L. Juliano. 1992. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J. Biol. Chem. 267:23439-23442.
46. Kupprion, C., K. Motamed, and E.H. Sage. 1998. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273:29635-29640.
47. Lane, T.F., M.L. Iruela-Arispe, and E.H. Sage. 1992. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J. Biol. Chem. 267:16736-16745.
48. Lane, T.F., M.L. Iruela-Arispe, R.S. Johnson, and E.H. Sage. 1994. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125:929-943.
49. Lee, J.D., N. Hempel, N.Y. Lee, and G.C. Blobe. 2010. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis. 31:175-183.
50. Lee, J.S., J.M. Suh, H.G. Park, E.J. Bak, Y.J. Yoo, and J.H. Cha. 2008a. Heparinbinding epidermal growth factor-like growth factor inhibits adipocyte differentiation at commitment and early induction stages. Differentiation. 76:478-487.
51. Lee, N.Y., B. Ray, T. How, and G.C. Blobe. 2008b. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J. Biol. Chem. 283:32527-32533.
52. Li, D.Y., L.K. Sorensen, B.S. Brooke, L.D. Urness, E.C. Davis, D.G. Taylor, B.B. Boak, and D.P. Wendel. 1999. Defective angiogenesis in mice lacking endoglin. Science. 284:1534-1537.
53. Liaw, L., M.P. Skinner, E.W. Raines, R. Ross, D.A. Cheresh, S.M. Schwartz, and C.M. Giachelli. 1995. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 95:713-724.
54. Lien, S.C., S. Usami, S. Chien, and J.J. Chiu. 2006. Phosphatidylinositol 3-kinase/Akt pathway is involved in transforming growth factor-beta1-induced phenotypic modulation of 10T1/2 cells to smooth muscle cells. Cell. Signal. 18:1270-1278.
55. Lindahl, P., B.R. Johansson, P. Levéen, and C. Betsholtz. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-245.
56. Ludbrook, S.B., S.T. Barry, C.J. Delves, and C.M. Horgan. 2003. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem. J. 369:311-318.
57. Lyons, R.M., J. Keski-Oja, and H.L. Moses. 1988. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J. Cell Biol. 106:1659-1665.
58. Motamed, K., and E.H. Sage. 1998. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J. Cell. Biochem. 70:543-552.
59. Motamed, K., D.J. Blake, J.C. Angello, B.L. Allen, A.C. Rapraeger, S.D. Hauschka, and E.H. Sage. 2003. Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: a role for protein kinase A. J. Cell. Biochem. 90:408-423.
60. Mu, D., S. Cambier, L. Fjellbirkeland, J.L. Baron, J.S. Munger, H. Kawakatsu, D. Sheppard, V.C. Broaddus, and S.L. Nishimura. 2002. The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J. Cell Biol. 157:493-507.
61. Munger, J.S., J.G. Harpel, F.G. Giancotti, and D.B. Rifkin. 1998. Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1. Mol. Biol. Cell. 9:2627-2638.
62. Munger, J.S., X. Huang, H. Kawakatsu, M.J. Griffiths, S.L. Dalton, J. Wu, J.F. Pittet, N. Kaminski, C. Garat, M.A. Matthay, et al. 1999. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 96:319-328.
63. Murphy-Ullrich, J.E., T.F. Lane, M.A. Pallero, and E.H. Sage. 1995. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J. Cell. Biochem. 57:341-350.
64. Nie, J., B. Chang, D.O. Traktuev, J. Sun, K. March, L. Chan, E.H. Sage, R. Pasqualini, W. Arap, and M.G. Kolonin. 2008. IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells. 26:2735-2745.
65. Owens, G.K. 1995. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75:487-517.
66. Pellinen, T., and J. Ivaska. 2006. Integrin traffic. J. Cell Sci. 119:3723-3731.
67. Puolakkainen, P.A., R.A. Brekken, S. Muneer, and E.H. Sage. 2004. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2:215-224.
68. Qu, Z.H., X.L. Zhang, T.T. Tang, and K.R. Dai. 2008. Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. Biochem. Biophys. Res. Commun. 370:332-337.
69. Raines, E.W., T.F. Lane, M.L. Iruela-Arispe, R. Ross, and E.H. Sage. 1992. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. USA. 89:1281-1285.
70. Ray, B.N., N.Y. Lee, T. How, and G.C. Blobe. 2010. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis. 31:435-441.
71. Reznikoff, C.A., D.W. Brankow, and C. Heidelberger. 1973. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res. 33:3231-3238.
72. Saharinen, J., M. Hyytiäinen, J. Taipale, and J. Keski-Oja. 1999. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 10:99-117.
73. Sanz-Rodriguez, F., M. Guerrero-Esteo, L.M. Botella, D. Banville, C.P. Vary, and C. Bernabéu. 2004. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J. Biol. Chem. 279:32858-32868.
74. Sato, Y., and D.B. Rifkin. 1989. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J. Cell Biol. 109:309-315.
75. Scaffidi, A.K., N. Petrovic, Y.P. Moodley, M. Fogel-Petrovic, K.M. Kroeger, R.M. Seeber, K.A. Eidne, P.J. Thompson, and D.A. Knight. 2004. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J. Biol. Chem. 279:37726-37733.
76. Schiemann, B.J., J.R. Neil, and W.P. Schiemann. 2003. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol. Biol. Cell. 14:3977-3988.
77. Schmierer, B., and C.S. Hill. 2007. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8:970-982.
78. Shi, Q., S. Bao, J.A. Maxwell, E.D. Reese, H.S. Friedman, D.D. Bigner, X.F. Wang, and J.N. Rich. 2004. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J. Biol. Chem. 279:52200-52209.
79. Stawowy, P., K. Graf, S. Goetze, M. Roser, M. Chrétien, N.G. Seidah, E. Fleck, and M. Marcinkiewicz. 2003. Coordinated regulation and colocalization of alphav integrin and its activating enzyme proprotein convertase PC5 in vivo. Histochem. Cell Biol. 119:239-245.
80. Stefansson, S., and D.A. Lawrence. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 383:441-443.
81. Thomas, M., M. Felcht, K. Kruse, S. Kretschmer, C. Deppermann, A. Biesdorf, K. Rohr, A.V. Benest, U. Fiedler, and H.G. Augustin. 2010. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J. Biol. Chem. 285:23842-23849.
82. von Tell, D., A. Armulik, and C. Betsholtz. 2006. Pericytes and vascular stability. Exp. Cell Res. 312:623-629.
83. Weaver, M.S., E.H. Sage, and Q. Yan. 2006. Absence of SPARC in lens epithelial cells results in altered adhesion and extracellular matrix production in vitro. J. Cell. Biochem. 97:423-432.
84. Weaver, M.S., G. Workman, and E.H. Sage. 2008. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J. Biol. Chem. 283:22826-22837.
85. Wipff, P.J., D.B. Rifkin, J.J. Meister, and B. Hinz. 2007. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J. Cell Biol. 179:1311-1323.
86. Yamashita, M., K. Fatyol, C. Jin, X. Wang, Z. Liu, and Y.E. Zhang. 2008. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell. 31:918-924.